Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System
ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE:STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of patients using the latest Genesis Robotic Magnetic Navigation (RMN) system by physicians of the nationally recognized Fred & Lena Meijer Heart Center, part of Corewell Health in Grand Rapids, Michigan.
Related news for (STXS)
- MoBot alert highlights: NASDAQ: GTI, NASDAQ: VWAV, NASDAQ: ADIL, NYSE: STXS, NASDAQ: ABP (07/28/25 08:00 AM)
- Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter
- 24/7 Market News Snapshot 28 July, 2025 – Stereotaxis, Inc. Common Stock (NYSE:STXS)
- Stereotaxis Reports 2025 First Quarter Financial Results
- Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025